Access the right information at the right time, with our intelligent clinical drug data API and in-depth knowledge database.
Learn about our solutions

Drug knowledge for all your needs

DrugBank Online at your fingertips

Search our knowledge base for drug interactions, pharmacology, chemical structures, targets, metabolism, & more. Download limited datasets, free for academic & non-commercial researchers.

Search now

Power your clinical software

Integrate our pharmaceutical knowledge base with our clinical drug data API. Scale usage & launch faster with flexible data modules. Empower users with relevant information & advanced insights.

Learn more

Discover or repurpose drugs

Identify repurposing opportunities, or build predictive machine learning models. Our structured, extensive datasets cover drugs in early stage research, clinical trials, & approval.

Learn More

What's trending

DrugBank top drugs
  1. Morphine
  2. Acetaminophen
  3. Acetylsalicylic acid
  4. Salbutamol
  5. Codeine
  6. Oxycodone
DrugBank top products
  1. Fortamet
  2. Norvasc
  3. Prilosec
  4. Truvada
  5. Zocor
  6. Humira
  7. Herceptin
  8. Flonase
  9. Plan-B
  10. Imodium
Featured Drug

Remdesivir

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.[A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families. Remdesivir activity against the Coronaviridae family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19.[A191427, A198810] Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.[L12174, L12177] Based on aggregate data, remdesivir was granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020. The FDA subsequently granted full approval for remdesivir as a COVID-19 treatment on October 22, 2020, while simultaneously updating the EUA to cover those patients not included under the approved indication. Remdesivir is currently marketed under the trademark name VEKLURY® by Gilead Sciences Inc. Remdesivir in combination with baricitinib for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 Novermber 2020.

Featured Info

COVID-19 Information Dashboard

We've put together a COVID-19 Information Dashboard, to provide a comprehensive summary of relevant COVID-19 research, in an effort to help researchers find the information they need quickly and effectively.

View the Dashboard

DrugBank is offered to the public as a freely available resource

DrugBank Online is offered to the public as a free-to-access resource. Use and re-distribution of the content of DrugBank Online or the DrugBank Data, in whole or in part, for any purpose requires a license. Academic users may apply for a free license for certain use cases and all other users require a paid license.
Cite DrugBank
Contact Sales
Apply for Academic License